Activin/follistatin in mouse lymphocytes
小鼠淋巴细胞中的激活素/卵泡抑素
基本信息
- 批准号:10660295
- 负责人:
- 金额:$ 2.62万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:1998
- 资助国家:日本
- 起止时间:1998 至 1999
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
We have demonstrated that activin is an autocrine regulator of matrix metalloproteinase (MMP) -2 production in mouse peritoneal macrophages. Although the expression of βA subunit and follistatin was detected, that of α and βB subunit was not found in macrophages by reverse transcription-polymerase chain reaction (RT-PCR), suggesting that macrophages produce activin (activin A) and its binding protein, follistatin, but not inhibin. LPS, a potent inflammatory stimulus, stimulated the production of activin βA subunit mRNA and activin activity from mactophages. LPS-stimulated activin production from macrophages was not affected by IFN-γ. The expression of both type I and type II activin receptors in mouse peritoneal macrophages suggests that activin produced by macrophages acts as an autocrine regulator of macrophage function. Gelatin zymography analysis revealed that the production of MMP-2 from macrophages was enhanced by activin. Exogenously added follistatin suppressed MMP-2 activity f … More rom macrophages, indicating that MMP-2 is regulated, at laeast in part, by endogenous activin in an autocrine manner. MMP-2 activity was regulated by activin and follistatin at a mRNA level as revealed by competitive RT-PCR. Neither activin nor follistatin affected the production of mRNA or the activity of MMP-9 from macrophages. Since MMP-2 constitutes the key and rate-limiting proteinase governing the degradation of basement membrane collagens, activin may have a role in migration and infiltration of macrophages through the basement membrane in an inflammatory state.Activin is a potent cell growth and differentiation factor in many biological systems. However, expression and function of activin in the immune system are so far unknown. Here we demonstrated mRNA expression of activin βA, the binding protein (follistatin), and the receptors in B lymphocytes. In addition, we also show the dynamic changes in mRNA expression of activin, follistatin and activin receptors in response to activation of B lymphocytes to exert activin's action. Activin βA mRNA level was increased in the cultured B lymphocytes by LPS, whereas follistatin mRNA was decreased. Consistent with changes in mRNA level, net activin activity in the culture supernatant of B lymphocytes was also increased by LPS. Furthermore, immunization of mice with ovalbumin resulted in the increased activin βA mRNA and decreased follistatin mRNA in B lymphocytes, suggesting regulation of activin activity in B lymphocytes not only in vitro but also in vivo. The LPS stimulation and the immunization resulted in decreases in mRNAs expression of all four and three activin receptors except for ActRI, respectively. Our findings indicate that B lymphocytes produce activin and are target for activin, which might be the possible role of activin as an autocrine regulator of B lymphocytes. Less
我们已经证明激活素是小鼠腹腔巨噬细胞中基质金属蛋白酶(MMP)-2产生的自分泌调节剂。逆转录-聚合酶链反应(RT-PCR)检测到βA亚基和卵泡抑素的表达,但未检测到α和βB亚基的表达,提示巨噬细胞产生激活素(activin A)及其结合蛋白卵泡抑素,而不产生卵泡抑素。LPS是一种强有力的炎症刺激物,刺激巨噬细胞产生激活素βA亚基mRNA和激活素活性。LPS刺激的巨噬细胞激活素的产生不受IFN-γ的影响。小鼠腹腔巨噬细胞中I型和II型激活素受体的表达表明巨噬细胞产生的激活素作为巨噬细胞功能的自分泌调节剂。明胶酶谱分析表明,MMP-2的生产从巨噬细胞激活素增强。外源性卵泡抑素抑制MMP-2活性, ...更多信息 从巨噬细胞,表明MMP-2的调节,至少部分,由内源性激活素自分泌的方式。竞争性RT-PCR结果显示激活素和卵泡抑素在mRNA水平调控MMP-2活性。激活素和卵泡抑素均不影响巨噬细胞MMP-9的mRNA表达和活性。由于MMP-2是控制基底膜胶原降解的关键和限速蛋白酶,激活素可能在炎症状态下巨噬细胞穿过基底膜的迁移和浸润中起作用。然而,迄今为止,激活素在免疫系统中的表达和功能尚不清楚。在此,我们证明了激活素βA、结合蛋白(卵泡抑素)和受体在B淋巴细胞中的mRNA表达。此外,我们还显示激活素,卵泡抑素和激活素受体的mRNA表达的动态变化响应于激活的B淋巴细胞发挥激活素的作用。LPS可使培养的B淋巴细胞激活素βA mRNA表达增加,而卵泡抑素mRNA表达降低。与mRNA水平的变化一致,LPS也增加了B淋巴细胞培养上清液中的净激活素活性。卵清蛋白免疫小鼠后,B淋巴细胞中激活素βA mRNA表达增加,卵泡抑素mRNA表达减少,提示激活素对B淋巴细胞活性的调节不仅在体外,而且在体内也存在。LPS刺激和免疫分别导致除ActRI外的所有四种和三种激活素受体的mRNA表达降低。我们的研究结果表明,B淋巴细胞产生激活素,并为激活素的目标,这可能是激活素作为B淋巴细胞的自分泌调节剂的可能作用。少
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
OGAWA Kenji其他文献
OGAWA Kenji的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('OGAWA Kenji', 18)}}的其他基金
Elucidation of Replication Mechanisms and Development of Drug Discovery Platforms Using Ebola Virus Replication Inhibitors
使用埃博拉病毒复制抑制剂阐明复制机制并开发药物发现平台
- 批准号:
18K05985 - 财政年份:2018
- 资助金额:
$ 2.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigation of neural mechanisms for sense of agency by using neurofeedback
使用神经反馈研究代理感的神经机制
- 批准号:
26540059 - 财政年份:2014
- 资助金额:
$ 2.62万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Function of the Bone Morphogenetic Protein in Immune System
骨形态发生蛋白在免疫系统中的功能
- 批准号:
15580269 - 财政年份:2003
- 资助金额:
$ 2.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Comparative investigation of tolerance trait of anticancer drugs in primary and metastatic lesions of gastrointestinal carcinoma
胃肠道癌原发灶与转移灶抗癌药物耐受性的比较研究
- 批准号:
14571235 - 财政年份:2002
- 资助金额:
$ 2.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
British Honor System
英国荣誉制度
- 批准号:
10610220 - 财政年份:1998
- 资助金额:
$ 2.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似国自然基金
肠上皮内γδT细胞诱导抗原特异性Treg的体内机制及其对肾移植慢性排斥的抑制作用研究
- 批准号:81170693
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
阿尔茨海默病患者外周血淋巴细胞P53介导的G1/S调控点功能障碍研究
- 批准号:81000539
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
VAV1蛋白与肿瘤浸润T淋巴细胞失能机制的实验研究
- 批准号:30740003
- 批准年份:2007
- 资助金额:10.0 万元
- 项目类别:专项基金项目
相似海外基金
Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)
精氨酸消耗联合铂类紫杉烷化疗对侵袭性变异前列腺癌 (AVPC) 的影响
- 批准号:
10715329 - 财政年份:2023
- 资助金额:
$ 2.62万 - 项目类别:
Therapeutic targeting of CD206+ TAMs to enhance adaptive and innate anti-tumor immune responses in metastatic castration-resistant prostate cancer
CD206 TAM 的治疗靶向增强转移性去势抵抗性前列腺癌的适应性和先天抗肿瘤免疫反应
- 批准号:
10731906 - 财政年份:2023
- 资助金额:
$ 2.62万 - 项目类别:
Mechanisms of immunosuppression in the development and progression of renal disease in Tuberous Sclerosis Complex
免疫抑制在结节性硬化症肾病发生和进展中的机制
- 批准号:
10658079 - 财政年份:2023
- 资助金额:
$ 2.62万 - 项目类别:
A novel dual-carrier ultrasmall nanomedicine for the treatment of stroma-rich pancreatic cancer
一种用于治疗富含基质的胰腺癌的新型双载体超小纳米药物
- 批准号:
10759720 - 财政年份:2023
- 资助金额:
$ 2.62万 - 项目类别:
FOXA1 regulates cytokine signaling and immune landscape in prostate cancer through ARID1A
FOXA1 通过 ARID1A 调节前列腺癌中的细胞因子信号传导和免疫景观
- 批准号:
10681898 - 财政年份:2023
- 资助金额:
$ 2.62万 - 项目类别:
Optimization of a Self-Adjuvanting Particle System for Delivering Respiratory Syncytial Virus Prefusion Protein
用于输送呼吸道合胞病毒预融合蛋白的自我辅助颗粒系统的优化
- 批准号:
10666079 - 财政年份:2023
- 资助金额:
$ 2.62万 - 项目类别:
Targeting KLF2 in macrophages to improve immune checkpoint therapy for hepatocellular cancer
靶向巨噬细胞中的 KLF2 以改善肝细胞癌的免疫检查点治疗
- 批准号:
10677187 - 财政年份:2023
- 资助金额:
$ 2.62万 - 项目类别:
Antigen-Presenting Cell Control of CD8+ T Cell Exhaustion in Cancer
癌症中 CD8 T 细胞耗竭的抗原呈递细胞控制
- 批准号:
10659843 - 财政年份:2023
- 资助金额:
$ 2.62万 - 项目类别:
Project 3: Hedgehog Inhibition to Enhance Response to ICI Therapy
项目 3:Hedgehog 抑制增强 ICI 治疗反应
- 批准号:
10713054 - 财政年份:2023
- 资助金额:
$ 2.62万 - 项目类别:














{{item.name}}会员




